| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WALTHAM, Mass.—BG Medicine announced the U.S. FDA has approved the first phase of its biomarker discovery project focusing on preclinical analysis of liver toxicity. Working with the National Center for Toxicological Research, the company will leverage its experiences in functional genomics, proteomics, metabolomics, and computational analysis to discover hepatotoxicity markers.
 
Liver toxicity has historically been a major contributor to late-stage failures of many drugs and therefore the rising costs associated with drug development. As such, it has been a target of the FDA's Critical Path Initiative and has fostered significant growth in the ADMET marketplace.
 
Representatives of seven pharmaceutical firms—Pfizer, Johnson & Johnson Pharmaceutical Research and Development, Mitsubishi Chemical Holdings, Orion, UCB, Sankyo, and Eisai—will sit on the project's scientific advisory board and provide funding. Applied Biosystems will likewise provide technology, service, and support, as well as in-kind contributions.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue